BriaCell closes $4M strategic investment by Prevail Partners at $8.63/share

BriaCell Therapeutics Corp.

Issued 463,408 common shares to Prevail Partners for aggregate gross proceeds of $4 million.
Price per share was US$8.63; TSX approved the transaction on May 18, 2023.
Proceeds to fund CRO clinical services and technologies for upcoming pivotal study in advanced metastatic breast cancer.
Shares subject to four-month-and-one-day hold period under Canadian securities laws.
Prevail Partners' affiliate, Prevail InfoWorks, will provide clinical services and real-time data analytics platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.